Global Serum-free Media Market Size study & Forecast, by Product (CHO Media, HEK 293 Media, BHK Media, Vero Medium, Stem Cell Medium, Other Serum-free Media), by Application (Biopharmaceutical Production, Monoclonal Antibodies, Vaccines Production, Tissue

Global Serum-free Media Market Size study & Forecast, by Product (CHO Media, HEK 293 Media, BHK Media, Vero Medium, Stem Cell Medium, Other Serum-free Media), by Application (Biopharmaceutical Production, Monoclonal Antibodies, Vaccines Production, Tissue Engineering & Regenerative Medicine, Other Therapeutic Proteins), by Type (Liquid Media, Semi-Solid & Solid Media), by End-User (Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, Other End-Users) and Regional Analysis, 2023-2030

Global Serum-free Media Market is valued approximately at USD 1.46 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 13.03% over the forecast period 2023-2030. Serum-free media contains proper ratios of nutrients and hormones because they don't require animal serum for cell growth. Serum-free media for cell culture has a number of advantages, including increased productivity and consistency as well as easier purification and downstream processing. In addition, serum-free media formulations can contain combinations of selective growth agents for specific cell types. Serum-free medium formulations are available for many primary cultures and cell lines, including hybridoma cell lines, Chinese hamster ovary (CHO) lines that produce recombinant proteins, and cell lines that act as hosts for virus production (e.g., 293, VERO, MDCK, MDBK). The market growth of serum-free media is driven by factors such as rising focus on cell-based therapeutics, growing production of new biopharmaceuticals and large scale manufacturing with CHO cells in cell culture.

According to Statista, the global cell culture market reached around USD 19.2 billion in 2022 and it is expected that by 2030, the market would be worth more than USD 33 billion, with a CAGR of 7.2%. More FDA approvals, clinical trials, and strategic initiatives such collaborations by the key market players is expanding the market. Moreover, increasing funding in stem cell research and rising awareness of media-based diagnostic testing may create abundant opportunities for the market in the forecast years. In September 2021, the California Institute for Regenerative Medicine awarded Stanford physician-researchers almost USD 31.0 million to begin the first-in-human stem cell clinical trials for the treatment of heart failure, stroke, and a specific form of spinal cord and brain tumor. However, the high cost of production process and high research and Development costs may stifle market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Serum-free Media Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share due to the existence of a strong R&D infrastructure and a supportive regulatory environment, both of which are quickly changing to accommodate the sector's continual scientific advancement. For instance, in November 2022, FUJIFILM Holdings Corporation invested USD 188.0 million in Research Triangle Park (RTP), North Carolina, to construct a manufacturing plant for serum-free media. However, Asia Pacific is expected to be the fastest growing region during the forecast period, due to more R&D and clinical trial programs for chronic and serious illnesses every year.

Major market player included in this report are:
Sartorius AG
FUJIFILM Holdings Corporation
Lonza Group AG
STEMCELL Technologies
PromoCell GmbH
Thermo Fisher Scientific Inc.
Corning Incorporated
FUJIFILM Irvine Scientific
Athena Environmental Sciences
Sartorius CellGenix

Recent Developments in the Market:
In November 2022, BioPharma Dynamics expanded their product range for the Gene & Cell Therapy sector to offer a range of serum-free and chemically specified cell medium solutions. The selection of cell media products comprises cell cryopreservation solutions, stem cell media, and immune cell media, all of which are appropriate for cell therapy applications.
In August 2022, Thermo Fisher Scientific Inc. expanded the cell culture media manufacturing plant in Grand Island, New York in order to enable the production of fresh vaccines and biologics.
In July 2022, Moderna, Inc. and Thermo Fisher Scientific Inc. entered a 15-year strategic collaboration agreement in order to facilitate the dedicated large-scale manufacturing of Spikevax, Moderna's COVID-19 vaccine, and other investigational mRNA therapies in its pipelines in the United States.

Global Serum-free Media Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, Application, Type, End-User, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
CHO Media
HEK 293 Media
BHK Media
Vero Media
Stem Cell Media
Other Serum-free Media

By Application:
Biopharmaceutical Production
Monoclonal Antibodies
Vaccines Production
Tissue Engineering & Regenerative Medicine
Other Therapeutic Proteins
By Type:
Liquid Media
Semi-solid & Solid Media

By End-User:
Pharmaceutical & Biotechnology Companies
Research & Academic Institutes
Other End-Users

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Sartorius AG
FUJIFILM Holdings Corporation
Lonza Group AG
STEMCELL Technologies
PromoCell GmbH
Thermo Fisher Scientific Inc.
Corning Incorporated
FUJIFILM Irvine Scientific
Athena Environmental Sciences
Sartorius CellGenix

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.